|
Sign In to gain access to subscriptions and/or personal tools.
|
Oxymetholone: I. Evaluation in a Comprehensive Battery of Genetic Toxicology and In Vitro Transformation Assays
Henry E. Holden
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Debbie Studwell
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Jenness B. Majeska
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877
Oxymetholone is generally assumed to be a nongenotoxic carcinogen. This assumption is based primarily on the results of an Ames test, existing data in repeat-dose toxicology studies, and the predicted results of a 2-yr National Toxicology Program (NTP) rat carcinogenicity bioassay. To provide a comprehensive assessment of its genotoxicity in a standard battery of mutagenicity assays, oxymetholone was tested in microbial and mammalian cell gene mutation assays, in an in vitro cytogenetics assay (human lymphocytes), and in an in vivo micronucleus assay. Oxymetholone was also tested in an in vitro morphologic transformation model using Syrian hamster embryo (SHE) cells. These studies were initiated and completed prior to the disclosure of the results of the NTP bioassay. Oxymetholone was tested at doses up to 5,000 µg/plate in the bacterial plate incorporation assay using 4 Salmonella strains and the WP2 uvrA (pKM101) strain of Escherichia coli. There was no induction of revertants up to the highest dose levels, which were insoluble as well as toxic. In the L5178Y tk+/- mouse lymphoma assay, doses up to 30 µg/ml reduced relative survival to  30% with no increase in mutants. Male or female human lymphocytes were exposed in vitro to oxymetholone for 24 hr without S9 or 3 hr with S9 and evaluated for the induction of chromosomal aberrations. There was no increase in aberration frequency over control levels and no difference between male and female cells. Peripheral blood from Tg.AC transgenic mice treated dermally for 20 wk with 0, 1.2, 6.0, or 12.0 mg/day of oxymetholone and from p53 transgenic mice treated orally by gavage for 26 wk with 125, 625, or 1,250 mg/kg/day of oxymetholone was evaluated for micronuclei in polychromatic and normochromatic erythrocytes. There was no difference in micronuclei frequency between control and treated animals. These results confirm that oxymetholone is not genotoxic in a comprehensive battery of mutagenicity assays. In the SHE assay, oxymetholone produced a significant increase in morphologically transformed colonies at dose levels of 13-18 µg/ml. The lack of genotoxicity of oxymetholone, the positive response in the in vitro transformation assay, and the results of transgenic mouse carcinogenicity assays will provide an interesting perspective on the results of an on-going NTP rat carcinogenicity bioassay.
Key Words: Oxymetholone • genetic toxicology • mutagenicity • Ames test • cytogenetics • micronucleus test • SHE assay • carcinogenicity
References
- Anonymous (1995). ANADROL®-50. In: Physician's Desk Reference, 49th ed. Medical Economics Data Production Co., Montvale, New Jersey, pp. 2458-2459.
- Bootman J. (1996). Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organized by the U.S. National Toxicology Program. Environ. Mol. Mutagen. 27: 237-243.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Buckley W., Yesalis C., Friedl K., Anderson W., Streit A., and Wright J. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. J. Am. Med. Assoc. 260: 3441-3445.[Abstract/Free Full Text]
- Clive D., Caspary W., Kirby PE, Krehl R., Moore M., Mayo J., and Oberly TJ (1987). Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutat. Res. 189: 143-156.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Donehower L. (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin. Cancer Biol. 7: 269-278.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Evans HJ and O'Riordan ML (1975). Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat. Res. 31: 135-148.[Web of Science][Medline]
[Order article via Infotrieve]
- Hennge UR, Baumann M., Maleba R., Brockmeyer N., and Goos M. (1996). Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br. J. Nutr. 75: 129-138.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Holden H., Majeska J., and Studwell D. (1997). A direct comparison of mouse and rat bone marrow and blood as target tissues in the micronucleus assay. Mutat. Res. 391: 87-89.[Web of Science][Medline]
[Order article via Infotrieve]
- Holden HE, Stoll RE, and Blanchard KT (1999). Oxymetholone: II. Evaluation in the Tg.AC transgenic mouse model for detection of carcinogens. Toxicol. Pathol. 27:507-512 (this issue).[Abstract/Free Full Text]
- Holden HE, Stoll RE, Spalding JW, and Tennant RW (1997). Evaluation of oxymetholone in the Tg.AC transgenic mouse model for accelerated carcinogenicity detection. Fundam. Appl. Toxicol. 36: 178-179.
- Holden HE, Stoll RE, Spalding JW, and Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J. Appl. Toxicol. 18: 19-24.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kastenbaum M., and Bowman K. (1970). Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9: 527-549.[Web of Science][Medline]
[Order article via Infotrieve]
- Kerckaert G., Brauninger R., LeBoeuf R., and Isfort R. (1996). Use of the Syrian hamster embryo cell transformation assay for carcinogenicity prediction of chemicals currently being tested by the National Toxicology Program in rodent bioassays. Environ. Health Perspect. 104: 1075-1084.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kerckaert G., Isfort R., Carr G., Aardema M., and LeBoeuf R. (1996). A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. Mutat. Res. 356: 65-84.[Web of Science][Medline]
[Order article via Infotrieve]
- LeBeouf R., Kerckaert G., Aardema M., Gibson D., Brauninger R., and Isfort R. (1996). The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutat. Res. 356: 85-127.[Web of Science][Medline]
[Order article via Infotrieve]
- Leder A., Kuo A., Cardiff R., Sinn E., and Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effect of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA 87: 9178-9182.[Abstract/Free Full Text]
- MacGregor JT, Wehr CM, Henika PR, and Shelby MD (1990). The erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam. Appl. Toxicol 14: 513-522.
- Maron DM and Ames BN (1983). Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113: 173-215.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- National Toxicology Program ( 1998). Management Status Report, April. Department of Health and Human Services, National Institutes of Health, National Institute for Envionmental Health Sciences, Research Triangle Park, North Carolina, p. 13.
- Stoll RE, Holden HE, Barthel CH, and Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53+l- transgenic mouse model. Toxicol. Pathol. 27: 513-518 (this issue).[Abstract/Free Full Text]
- Studwell D., Holden HE, and Majeska JB (1997). Oxymetholone: A non-genotoxic carcinogen? Environ. Mol. Mutagen. 29(S28): 49.
- Zeiger E., Anderson B., Haworth S., Lawlor T., and Mortelmans K. (1991). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19: 2-141.[CrossRef][Web of Science]
Toxicologic Pathology, Vol. 27, No. 5,
501-506 (1999)
DOI: 10.1177/019262339902700501
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H. E. Holden, R. E. Stoll, and K. T. Blanchard
Oxymetholone: II. Evaluation in the Tg.AC Transgenic Mouse Model for Detection of Carcinogens
Toxicol Pathol,
September 1, 1999;
27(5):
507 - 512.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. E. Stoll, H. E. Holden, C. H. Barthel, and K. T. Blanchard
Oxymetholone: III. Evaluation in the p53+/- Transgenic Mouse Model
Toxicol Pathol,
September 1, 1999;
27(5):
513 - 518.
[Abstract]
[PDF]
|
|
|
|
|
